This list is an analysis based on recent market events. It's not an investment recommendation.
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Show more...
FAQ
What is Qlucore AB (publ) stock price today?▼
The current price of NOVKAN.ST is SEK0.03 SEK — it has decreased by -43.95% in the past 24 hours. Watch Qlucore AB (publ) stock price performance more closely on the chart.
What is Qlucore AB (publ) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Qlucore AB (publ) stocks are traded under the ticker NOVKAN.ST.
What is Qlucore AB (publ) market cap?▼
Today Qlucore AB (publ) has the market capitalization of 3.03M
What is Qlucore AB (publ) revenue for the last year?▼
Qlucore AB (publ) revenue for the last year amounts to 0 SEK.
What is Qlucore AB (publ) net income for the last year?▼
NOVKAN.ST net income for the last year is -136.72M SEK.
How many employees does Qlucore AB (publ) have?▼
As of September 05, 2026, the company has 5 employees.
In which sector is Qlucore AB (publ) located?▼
Qlucore AB (publ) operates in the Other sector.
When did Qlucore AB (publ) complete a stock split?▼
Qlucore AB (publ) has not had any recent stock splits.
Where is Qlucore AB (publ) headquartered?▼
Qlucore AB (publ) is headquartered in Solna, Sweden.